Search clinical trials for: Nivolumab and Ipilimumab

Total 272056 results

Case Comprehensive Cancer Center

Completed

Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

Metastatic Renal Cell Carcinoma

United States
University of Erlangen-Nürnberg Medical School

Completed

Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition (ST-ICI)

Metastatic Cancer

Germany
NYU Langone Health

Completed

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

GBM | MGMT-unmethylated Glioblastoma (GBM)

United States
Washington University School of Medicine
NovoCure Ltd.

Terminated

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Melanoma With Brain Metastasis

United States
HonorHealth Research Institute
NovoCure Ltd.

Recruiting

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Uveal Melanoma

United States
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)

Recruiting

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma (RadVax)

Metastatic Melanoma

United States
Massachusetts General Hospital
Bristol-Myers Squibb

Recruiting

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Pancreatic Cancer | Microsatellite Stable Colorectal Cancer | MSI High Colorectal Cancer

United States
National Cancer Centre, Singapore
National Taiwan University Hospital; National University of Singapore

Recruiting

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Singapore
Georgetown University
Exelixis; Hackensack Meridian Health; MedStar Franklin Square Medical Center

Suspended

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Melanoma

United States
Massachusetts General Hospital
Bristol-Myers Squibb

Active, not recruiting

Nivolumab+Ipilimumab+RT in MSS mCRC

Metastatic Microsatellite Stable Colorectal Cancer

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Nivolumab Plus Ipilimumab in Thyroid Cancer

Thyroid Cancer

United States
SQZ Biotechnologies

Terminated

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Adult Solid Tumor

United States
Ludwig Institute for Cancer Research
Bristol-Myers Squibb; Conquer Cancer Foundation

Completed

Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma

Melanoma

United States
PrECOG, LLC.
AstraZeneca; University of Sydney; Thoracic Oncology Group Australasia (TOGA)

Active, not recruiting

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Mesothelioma

United States, Australia, New Zealand
Spanish Oncology Genito-Urinary Group
Bristol-Myers Squibb; Syntax for Science, S.L

Active, not recruiting

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Metastatic Hormone-sensitive Prostate Cancer

Spain
Weill Medical College of Cornell University
Bristol-Myers Squibb

Terminated

Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

Non Small Cell Lung Cancer Metastatic

United States
Massachusetts General Hospital
Bristol-Myers Squibb

Active, not recruiting

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer

United States
Australian and New Zealand Urogenital and Prostate...
Bristol-Myers Squibb

Active, not recruiting

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation Carcinoma

Australia
Columbia University

Withdrawn

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb; Amgen

Active, not recruiting

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Colon Cancer

United States
Herlev Hospital
Bristol-Myers Squibb

Completed

Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients (CheckPAC)

Metastatic Pancreatic Cancer | Metastatic Biliary Tract Cancer

Denmark
SQZ Biotechnologies

Completed

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Adult Solid Tumor

United States, Canada, Germany
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Active, not recruiting

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Metastatic Melanoma | Metastasis to Brain

United States
7 Hills Pharma, LLC

Recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Melanoma | Kidney Cancer | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Non Small Cell Lung Cancer | Skin Cancer | Metastasis | Advanced Solid Tumor | Advanced Cancer | Renal Cell Cancer | Hepatocellular Cancer | Mismatch Repair Deficiency | Pleural Mesothelioma | MSI-High | Anaplastic Lymphoma... and other conditions

United States
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

GastroEsophageal Cancer | Adenocarcinoma of the Stomach

Germany
Memorial Sloan Kettering Cancer Center

Completed

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Uveal Melanoma

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (CheckMate204)

Melanoma

United States
Medical University of South Carolina
Bristol-Myers Squibb

Withdrawn

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Canada
M.D. Anderson Cancer Center

Recruiting

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

ICB-refractory Melanoma

United States
Imperial College London
Bristol-Myers Squibb

Recruiting

Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma (PRIME-HCC)

Hepatocellular Carcinoma

United Kingdom
Bristol-Myers Squibb

Completed

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Advanced Solid Cancers

United States, Canada
Bristol-Myers Squibb

Terminated

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Advanced Cancer

Chile, United States, Argentina, Australia, Belgium, Canada, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Romania, Spain, Switzerland
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Malignant Melanoma Stage III

Austria, Netherlands, Australia, Sweden
Children's National Research Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Melanoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid Tumor

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Advanced or Metastatic Melanoma

United States
Georgetown University
Bristol-Myers Squibb; M.D. Anderson Cancer Center; University of Colorado, Denver and other collaborators

Terminated

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Mucosal Melanoma | Acral Lentiginous Melanoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Head and Neck Cancer

United States
Melanoma Institute Australia
Bristol-Myers Squibb; Melanoma and Skin Cancer Trials Limited

Active, not recruiting

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (ABC)

Melanoma | Brain Metastases

Australia
Salma Sabbour
Bristol-Myers Squibb; Rutgers Cancer Institute of New Jersey; BeyondSpring Pharmaceuticals...

Active, not recruiting

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Lung Cancer | SCLC

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India (CheckMate 7C9)

Kidney Neoplasms

India
Bristol-Myers Squibb

Completed

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Melanoma

United States
Jounce Therapeutics, Inc.

Terminated

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

Cancer

United States
Centre Leon Berard

Active, not recruiting

Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03)

Breast Cancer | Triple Negative Breast Neoplasms

France
Assaf-Harofeh Medical Center

Unknown

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Soft Tissue Sarcoma | Osteosarcoma | Chondrosarcoma | Bone Sarcoma | Desmoplastic Small Round Cell Tumor | Gastrointestinal Stromal Sarcoma | Ewing's Tumor Metastatic | Ewing's Tumor Recurrent
University of Utah
Bristol-Myers Squibb

Completed

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Withdrawn

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Hematopoietic and Lymphoid Cell Neoplasm | Lynch Syndrome | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central... and other conditions

United States, Canada
University Health Network, Toronto
Bristol-Myers Squibb

Recruiting

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS)

Non Small Cell Lung Cancer

Canada
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X)

Melanoma Stage Iv

Australia, Norway
University of Michigan Rogel Cancer Center

Active, not recruiting

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Metastatic Melanoma | Liver Metastases | Melanoma, Mucosal | Melanoma, Ocular | Melanoma, Cutaneous

United States

Search clinical trials for: Nivolumab and Ipilimumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations